



## Surface Oncology to Participate in the Gilmartin Group Emerging Growth Company Showcase

August 24, 2022

CAMBRIDGE, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- [Surface Oncology](#) (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in a fireside chat at the virtual Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31, 2022 at 2:30 p.m. ET.

A live webcast of the presentation may be accessed by visiting the Investors & Media section of the Surface Oncology website at <https://investors.surfaceoncology.com/>. In addition, a replay of the webcast will be available on the company's website following the presentation.

### About Surface Oncology

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on selectively depleting regulatory T cells in the tumor microenvironment via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRI (GSK4381562, formerly SRF813; Phase 1). Surface's novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit [www.surfaceoncology.com](http://www.surfaceoncology.com).

### Contact

Scott Young  
(617) 865-3250  
[syoung@surfaceoncology.com](mailto:syoung@surfaceoncology.com)



Source: Surface Oncology, Inc.